Credit: Unsplash / CC0 Public Domain
Two relatively new but increasingly used diabetes drugs (with one of those classes now approved for use in heart failure in people with or without diabetes) may be more effective in people of Asian background than in people of white background, according to new data.
The study, published in Diabetes Care and led by the University of Glasgow, found that the diabetes drug classes GLP-1 receptor agonists and SGLT2 inhibitors can better reduce the risk of heart attack and stroke, as well as heart failure and death from heart disease. respectively.
People of Asian backgrounds, including South Asian and East Asian people, have a greater exposure to type 2 diabetes than people of white backgrounds.
Of the antihyperglycemic drug classes used to treat diabetes, the only drug classes GLP-1 receptor agonists and SGLT2 inhibitors are the only ones that show consistent benefits in cardiovascular outcomes. In this study, researchers analyzed data from six studies with SGLT2is; four diabetes studies and two heart failure outcome studies. They also analyzed data from six diabetes outcome studies for the GLP-1 receptor agonist class.
The study found a greater benefit of GLP-1RA therapy for heart attack and stroke risks in people of Asian background compared to people with white background for all types of drug tested. In addition, SGLT2i drugs were at least as good at reducing the risk of serious cardiovascular events in people with diabetes in Asians, but may have a better effect on heart failure outcomes in this group than whites in the heart failure studies.
Naveed Sattar, Professor of Metabolic Medicine at the Department of Cardiovascular and Medical Sciences, University of Glasgow, said: “These data show something potentially exciting for doctors treating Asians with diabetes Stroke risks in people with diabetes are exciting as diabetes is in many Asian populations occurs more often and it helps to find new ways to reduce their cardiovascular risks. “
“At the same time, potentially better results in Asians with heart failure with SGLT2 inhibitors are also exciting. Such results need to be confirmed now, and future studies should better subdivide people from Asian backgrounds into different subgroups so that we can see if the results apply to everyone with an Asian background or certain subgroups. “
The paper “Meta-analyzes of results from randomized outcome studies comparing the cardiovascular effects of SGLT2is and GLP-1RA in Asian and white patients with and without type 2 diabetes” was published in Diabetes Care.
Certain diabetes medications have been linked to a lower risk of serious heart problems
More information:
Meta-analyzes of results from randomized outcome studies comparing the cardiovascular effects of SGLT2i and GLP-1RA in Asian and white patients with and without type 2 diabetes. Diabetes treatment. Provided by the University of Glasgow
Quote: Two New Diabetes Drugs May Work Better in Asians (2021, March 12), accessed March 12, 2021 from https://medicalxpress.com/news/2021-03-diabetes-drugs-asian-people.html were
This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.
